Authors: Christiansen, JS Bengtsson, BA Thorner, MO Hintz, R Sonksen, PH Cohen, P Clemmons, D Strasburger, CJ Carlsson, L Tanaka, T Robinson, I Jorgensen, JO Johannson, G Clayton, PE Cowell, CT Malozowski, SN Hankinson, S Yee, D Baxter, R Swerdlow, A Rosenfeld, R Fradkin, JE Nishi, Y Monson, JP van den Berghe, G Carroll, PV Takala, J van der Lely, AJ Pollak, MN LeRoith, D Tachibana, K Kappelgaard, AM Langbakke, I Lippe, B Wilton, P Stein, P Salazar, DE Maneatis, T Blethen, SL Cutler, GB Blum, WF Svanberg, E Gertner, JM Shimatsu, A Takahashi, H

Citation: Js. Christiansen et al., Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the growth hormone research society, J CLIN END, 86(5), 2001, pp. 1868-1870

Authors: de Lacerda, L Carvalho, JAR Stannard, B Werner, H Boguszewski, MCS Sandrini, R Malozowski, SN LeRoith, D Underwood, LE

Citation: L. De Lacerda et al., In vitro and in vivo responses to short-term recombinant human insulin-like growth factor-1 (IGF-1) in a severely growth-retarded girl with ring chromosome 15 and deletion of a single allele for the type 1 IGF receptor gene, CLIN ENDOCR, 51(5), 1999, pp. 541-550